Table 2.
Change in circulatory EPCs and SPP of the ischemic foot before and after HBO therapy.
| Variables | Pre-HBO | Post-HBO | P-Value |
|---|---|---|---|
| Flow cytometry (%) prior to and at 5th HBO therapy | |||
| CD34+/KDR+/CD45dim | 17.3 ± 15.3 | 22.1 ± 18.0 | 0.145 |
| CD34+/CD133+/CD45dim | 13.8 ± 9.8 | 20.2 ± 13.4 | <0.001 |
| CD31+/CD133+/CD45dim | 12.9 ± 11.7 | 19.1 ± 13.9 | 0.012 |
| CD34+/CD133+/KDR+ | 2.9 ± 2.1 | 5.3 ± 8.7 | 0.105 |
| CD34+ | 82.9 ± 85.7 | 115.9 ± 99.1 | 0.001 |
| Microcirculatory assessment (SPP, mmHg) 2 weeks after HBO therapy | |||
| Dorsal foot | 67.6 ± 24.4 | 75.9 ± 25.7 | 0.088 |
| Plantar foot | 57.2 ± 20.9 | 79.9 ± 30.8 | 0.007 |
| Lateral foot | 72.1 ± 26.5 | 79.2 ± 19.3 | 0.535 |
| Medial foot | 57.5 ± 24.6 | 78.9 ± 43.1 | 0.196 |
| Mean SPP of the ischemic foot | 62.1 ± 18.1 | 75.4 ± 20.3 | 0.003 |
Abbreviations: EPCs = endothelial progenitor cells; SPP = skin perfusion pressure; HBO = hyperbaric oxygen. Data are expressed as mean ± SD or % (n).